Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07799194 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

For Patients With Early-Stage Non-Small Cell Lung Cancer or Lung Oligo-metastatic Tumor, Applying Pulsed Electric Field Energy Through Percutaneous Approach To Ablate the Tumor and Evaluate the Safety and Initial Efficacy.

StatusNot Yet Recruiting
PhaseNot applicable
Started2026-09
View on ClinicalTrials.gov ↗
The goal of this observational study is to evaluate the performances of a percutaneous Pulsed Electrical Field (PEF) ablation to treat patients with primary early-stage lung cancer (NSCLC) or lung oligometastatic Tumors who are unresectable or refusal surgery/Radiotherapy. The main questions the study aims to answer are: The safety and technical feasibility of the PEF ablation. The preliminary efficacy of the PEF ablation for target lesion in lung Patients who meet the inclusion/exclusion criteria will be given percutaneous PEF ablation to the target lesions under general anesthesia. Then follow-up to 12 months to monitor any progression by about 3 months interval. Target Subject: Patients with early-stage primary non-small cell lung cancer(NSCLC) or pulmonary oligometastatic tumors who are not surgical resectable or unsuitable for surgery/radiotherapy
Trial Details
NCT Number NCT07799194
Lead Sponsor Energenx Medical LTD.
Conditions Lung Cancer (NSCLC)
Enrollment 10 participants
Start Date 2026-09
Primary Completion 2027-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-03